Abstract
Endocrine resistance is a major obstacle to hormonal therapy for breast cancers. Although reduced expression of estrogen receptor-α (ER-α) is a known contributing factor to endocrine resistance, the mechanism of ER-α downregulation in endocrine resistance is still not fully understood. Here we report that CUE domain–containing protein-2 (CUEDC2), a ubiquitin-binding motif–containing protein, is a key factor in endocrine resistance in breast cancer. We show that CUEDC2 modulates ER-α protein stability through the ubiquitin-proteasome pathway. Through the study of specimens from a large cohort of subjects with breast cancer, we found a strong inverse correlation between CUEDC2 and ER-α protein expression. Notably, subjects with tumors that highly expressed CUEDC2 had poor responsiveness to tamoxifen treatment and high potential for relapse. We further show that ectopic CUEDC2 expression impaired the responsiveness of breast cancer cells to tamoxifen. Therefore, our findings suggest that CUEDC2 is a crucial determinant of resistance to endocrine therapies in breast cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Donaldson, K.M., Yin, H., Gekakis, N., Supek, F. & Joazeiro, C.A. Ubiquitin signals protein trafficking via interaction with a novel ubiquitin binding domain in the membrane fusion regulator, Vps9p. Curr. Biol. 13, 258–262 (2003).
Ponting, C.P. Proteins of the endoplasmic-reticulum–associated degradation pathway: domain detection and function prediction. Biochem. J. 351, 527–535 (2000).
Shih, S.C. et al. A ubiquitin-binding motif required for intramolecular monoubiquitylation, the CUE domain. EMBO J. 22, 1273–1281 (2003).
Zhang, P.J. et al. CUE domain containing 2 regulates degradation of progesterone receptor by ubiquitin-proteasome. EMBO J. 26, 1831–1842 (2007).
Li, H.Y. et al. Deactivation of the kinase IKK by CUEDC2 through recruitment of the phosphatase PP1. Nat. Immunol. 9, 533–541 (2008).
Harvey, J.M., Clark, G.M., Osborne, C.K. & Allred, D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 17, 1474–1481 (1999).
Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351, 1451–1467 (1998).
Nadji, M., Gomez-Fernandez, C., Ganjei-Azar, P. & Morales, A.R. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am. J. Clin. Pathol. 123, 21–27 (2005).
Osborne, C.K., Schiff, R., Fuqua, S.A. & Shou, J. Estrogen receptor: current understanding of its activation and modulation. Clin. Cancer Res. 7, 4338s–4342s (2001).
Klinge, C.M. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res. 29, 2905–2919 (2001).
Schiff, R., Massarweh, S., Shou, J. & Osborne, C.K. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin. Cancer Res. 9, 447S–454S (2003).
Ma, C.X. et al. Human aromatase: gene resequencing and functional genomics. Cancer Res. 65, 11071–11082 (2005).
Ingle, J.N. Pharmacogenomics of tamoxifen and aromatase inhibitors. Cancer 112, 695–699 (2008).
Johnston, S.R. & Dowsett, M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat. Rev. Cancer 3, 821–831 (2003).
Baum, M. et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359, 2131–2139 (2002).
Jensen, E.V. & Jordan, V.C. The estrogen receptor: a model for molecular medicine. Clin. Cancer Res. 9, 1980–1989 (2003).
MacGregor, J.I. & Jordan, V.C. Basic guide to the mechanisms of antiestrogen action. Pharmacol. Rev. 50, 151–196 (1998).
Jordan, V.C. & O'Malley, B.W. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J. Clin. Oncol. 25, 5815–5824 (2007).
Clarke, R. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22, 7316–7339 (2003).
Musgrove, E.A. & Sutherland, R.L. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9, 631–643 (2009).
Riggins, R.B., Bouton, A.H., Liu, M.C. & Clarke, R. Antiestrogens, aromatase inhibitors and apoptosis in breast cancer. Vitam. Horm. 71, 201–237 (2005).
Ring, A. & Dowsett, M. Mechanisms of tamoxifen resistance. Endocr. Relat. Cancer 11, 643–658 (2004).
Johnston, S.R. et al. Changes in estrogen receptor, progesterone receptor and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res. 55, 3331–3338 (1995).
Chu, I. et al. Src promotes estrogen-dependent estrogen receptor α proteolysis in human breast cancer. J. Clin. Invest. 117, 2205–2215 (2007).
Shao, W., Keeton, E.K., McDonnell, D.P. & Brown, M. Coactivator AIB1 links estrogen receptor transcriptional activity and stability. Proc. Natl. Acad. Sci. USA 101, 11599–11604 (2004).
Fan, M., Nakshatri, H. & Nephew, K.P. Inhibiting proteasomal proteolysis sustains estrogen receptor-α activation. Mol. Endocrinol. 18, 2603–2615 (2004).
Sutherland, R.L. & Musgrove, E.A. Cyclins and breast cancer. J. Mammary Gland Biol. Neoplasia 9, 95–104 (2004).
Kenny, F.S. et al. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor–positive breast cancer. Clin. Cancer Res. 5, 2069–2076 (1999).
Olopade, O.I. et al. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J. Sci. Am. 3, 230–237 (1997).
Bernoux, A. et al. Estrogen receptor negative and progesterone receptor positive primary breast cancer: pathological characteristics and clinical outcome. Institut Curie Breast Cancer Study Group. Breast Cancer Res. Treat. 49, 219–225 (1998).
Yamashita, H. Current research topics in endocrine therapy for breast cancer. Int. J. Clin. Oncol. 13, 380–383 (2008).
Gown, A.M. Current issues in ER and HER2 testing by IHC in breast cancer. Mod. Pathol. 21 Suppl 2, S8–S15 (2008).
Lippman, M.E. & Allegra, J.C. Quantitative estrogen receptor analyses: the response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer 46, 2829–2834 (1980).
Jaiyesimi, I.A., Buzdar, A.U., Decker, D.A. & Hortobagyi, G.N. Use of tamoxifen for breast cancer: twenty-eight years later. J. Clin. Oncol. 13, 513–529 (1995).
Normanno, N. et al. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr. Relat. Cancer 12, 721–747 (2005).
Baselga, J. & Norton, L. Focus on breast cancer. Cancer Cell 1, 319–322 (2002).
Arpino, G., Wiechmann, L., Osborne, C.K. & Schiff, R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr. Rev. 29, 217–233 (2008).
Baldwin, A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J. Clin. Invest. 107, 241–246 (2001).
Kim, D.W. et al. Activation of NF-κB/Rel occurs early during neoplastic transformation of mammary cells. Carcinogenesis 21, 871–879 (2000).
Gutierrez, M.C. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2 and p38 mitogen-activated protein kinase. J. Clin. Oncol. 23, 2469–2476 (2005).
Rochefort, H., Glondu, M., Sahla, M.E., Platet, N. & Garcia, M. How to target estrogen receptor–negative breast cancer? Endocr. Relat. Cancer 10, 261–266 (2003).
Sharma, D., Saxena, N.K., Davidson, N.E. & Vertino, P.M. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res. 66, 6370–6378 (2006).
Giacinti, L., Claudio, P.P., Lopez, M. & Giordano, A. Epigenetic information and estrogen receptor α expression in breast cancer. Oncologist 11, 1–8 (2006).
Pan, X. et al. Induction of SOX4 by DNA damage is critical for p53 stabilization and function. Proc. Natl. Acad. Sci. USA 106, 3788–3793 (2009).
Acknowledgements
We thank Z. Liu for critical reading of the manuscript, L. Hu for assistance with statistical analysis and Q. Ye at Beijing Institute of Biotechnology for DBD-ER-α plasmids. This work was supported by grants from the China National Natural Science Foundation (No. 91029733, No. 30830097 and No. 30900754), the China National High Technology Research and Development Program (Grant 2009AA02Z103), the China National Basic Research Program (Grant 2010CB911900, 2010CB529404), the Key State Science and Technology Projects (2009ZX09503-001, 2009ZX09501-031, 2009ZX09301-002 and 2008ZX10002-016). Work conducted at Thomas Jefferson University is funded in part by a Pennsylvania Department of Health grant (to C.W.).
Author information
Authors and Affiliations
Contributions
X.-M.Z., T.Z. and C.W. supervised the project. X.P., T.Z. and J.Z. designed and conducted the experiments, including immunoprecipitation, RT-PCR, western blotting and drug sensitivity studies. Y.-H.T., under the supervision of L.-X.W., obtained clinical samples and did immunohistochemistry analysis. Y. Cao constructed the CRD. M.Y. and R.M. prepared CUEDC2-specific antibody. B.L., Z.-F.B. and J.-H.M. constructed stable cell lines. X.P., C.Z., Z.J. and W.-L.G. carried out animal experiments. Y. Chen, Y.-F.G., P.-J.Z. and W.-N.Z. contributed to the preparation of cDNA vector constructs. X.P., T.Z., C.W., X.-M.Z and H.-Y.L. analyzed the data. X.P. and Y.-H.T. did the statistical analyses. X.-M.Z., X.P., T.Z. and A.-L.L. wrote the manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–6, Supplementary Table 1 and Supplementary Methods (PDF 495 kb)
Rights and permissions
About this article
Cite this article
Pan, X., Zhou, T., Tai, YH. et al. Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer. Nat Med 17, 708–714 (2011). https://doi.org/10.1038/nm.2369
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.2369
This article is cited by
-
The crosstalk between ubiquitination and endocrine therapy
Journal of Molecular Medicine (2023)
-
Xihuang pill facilitates glioma cell pyroptosis via the POU4F1/STAT3 axis
Functional & Integrative Genomics (2023)
-
Molecular crosstalk between CUEDC2 and ERα influences the clinical outcome by regulating mitosis in breast cancer
Cancer Gene Therapy (2022)
-
PTEN promoter methylation predicts 10-year prognosis in hormone receptor-positive early breast cancer patients who received adjuvant tamoxifen endocrine therapy
Breast Cancer Research and Treatment (2022)
-
CUEDC2 controls osteoblast differentiation and bone formation via SOCS3–STAT3 pathway
Cell Death & Disease (2020)